The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An open label, multicenter, phase I/II study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors.
 
Mark R. Middleton
Honoraria - Amgen; Roche
Consulting or Advisory Role - BiolineRx; Bristol-Myers Squibb; CytomX Therapeutics; Immunocore; Johnson & Johnson; Merck; Newlink Genetics; Novartis; RigonTEC
Research Funding - Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Immunocore (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Replimune (Inst); RigonTEC (Inst); Roche (Inst); TC Biopharm (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Merck
 
Joseph J. Sacco
Honoraria - Amgen; Bristol-Myers Squibb; Immunocore; MSD
Consulting or Advisory Role - Delcath Systems; Immunocore; MSD
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Immunocore (Inst); MSD (Inst); Replimune (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
Jaime R. Merchan
Consulting or Advisory Role - Exelixis
Research Funding - Astellas Oncology (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Genentech (Inst); Lilly (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Replimune (Inst); Rexahn Pharmaceuticals (Inst); Seagen (Inst); Sillajen (Inst); T-cagen (Inst); Vyriad (Inst)
 
Brendan D. Curti
Consulting or Advisory Role - Alligator Bioscience; Eisai
Speakers' Bureau - Bristol-Myers Squibb; Prometheus
Research Funding - Bristol-Myers Squibb (Inst); Galectin Therapeutics (Inst); MedImmune (Inst); Prometheus (Inst); Viralytics (Inst)
Patents, Royalties, Other Intellectual Property - Biomarkers for OX40 response (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MedImmune; Prometheus
 
Ari M. Vanderwalde
Honoraria - AstraZeneca
Consulting or Advisory Role - Bristol-Myers Squibb; Caris Life Sciences; Compugen; Genentech/Roche; Immunocore
Research Funding - Amgen (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); Polynoma (Inst); Replimune (Inst)
 
Anna Claire Olsson-Brown
No Relationships to Disclose
 
Francesca Aroldi
No Relationships to Disclose
 
Nicos Fotiadis
No Relationships to Disclose
 
Scott Baum
No Relationships to Disclose
 
Robert S. Coffin
Employment - Replimune
Leadership - Replimune
Stock and Other Ownership Interests - Replimune
Research Funding - Replimune
Patents, Royalties, Other Intellectual Property - Replimune
 
Howard Kaufman
Employment - Replimune
Leadership - Replimune
Honoraria - SapVax
Consulting or Advisory Role - SapVax
Research Funding - Merck (Inst)
 
Kevin J. Harrington
Honoraria - Amgen; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Pfizer; Replimune
Consulting or Advisory Role - Amgen (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); Merck Sharp & Dohme; Pfizer (Inst)
Speakers' Bureau - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim